Actis

In 1996, when Claude Bébéar, chairman of AXA, asked Dominique Senequier to create a private equity arm for the insurer, a remarkable journey began. Bébéar promised to invest one franc for every two she raised from outside investors, a challenge that ignited a fierce determination in the young company to win clients through exceptional service and outstanding investment performance. Starting with just a $100m French Buyout fund and two external clients, the company steadily expanded into new asset classes and built a powerful international network across Europe, North America, and Asia. The pivotal moment arrived in 2013, when Dominique Senequier led an employee buyout of AXA Private Equity, creating Ardian – an independent private investment firm where approximately 80% of employees became owners. This independence unlocked a new chapter of accelerated growth, transforming the company into a global diversified private markets firm managing $196bn in assets. From those humble beginnings, Ardian has evolved into a world-leading organization with over 1,000 employees across 20 offices worldwide, mastering change to create lasting value for all stakeholders.

ARCHIMED is a global private equity firm dedicated exclusively to healthcare industries, founded in 2014 with a singular mission: to accelerate the development of healthcare solutions that benefit patients worldwide. The firm focuses on small-cap and mid-cap growth buyout transactions across eight targeted healthcare sectors - Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, Pharma Services, and Animal & Environmental Health. What sets ARCHIMED apart is its integrated approach combining operational, medical, scientific, and financial expertise, allowing the firm to serve as both a strategic and financial partner to healthcare businesses across Europe, North America, and Asia. With over 200 team members representing 35+ nationalities, ARCHIMED manages €8 billion across its funds and has invested in more than 80 companies representing over €50 billion in combined value. The firm's strategy is built on a proprietary market segmentation called MedSeg, which splits healthcare industries into 400+ sub-sectors that are individually assessed and prioritized. ARCHIMED's transatlantic platform supports portfolio companies through internationalization, innovation, M&A, and operational excellence. The firm delivers superior returns to investors - all ARCHIMED funds rank as top-decile performers - while maintaining a strong commitment to impact investing through its EURÊKA Foundation, which returns 5% of carried interest profits to the community.